Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles ...

Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorablesafety ...

This was not the first presentation on STI-571, but it was the one that would change everything: The New England Journal of ...

Leukemia and lymphoma are cancers that affect the blood or bone marrow. Fifteen percent of people with leukemia have chronic myeloid leukemia (CML), which has seen a 55% jump in new cases over the ...

An advocate discusses vital patient-provider conversations to promote the best care for individuals with chronic myeloid leukemia. Receiving a diagnosis of chronic myeloid leukemia (CML) can be ...

The ASH oral presentation today reports data from the ongoing dose escalation and dose expansion parts of the CARDINAL study of TERN-701 in patients with previously treated CML. As of the September 13 ...

The survival prognosis for patients with chronic phase CML has greatly improved since the introduction of TKIs, with some studies showing life expectancy close to the general population. Nonetheless, ...

Most — though not all — side effects from chronic myeloid leukemia treatment improve over time, an expert said. Most side effects from chronic myeloid leukemia (CML) treatment are manageable and will ...

CD56 Expression Is an Indicator of Poor Clinical Outcome in Patients With Acute Promyelocytic Leukemia Treated With Simultaneous All-Trans-Retinoic Acid and Chemotherapy PURPOSE: Recombinant ...

A study from a major cancer center collected data on 2857 patients with Ph+ CML, most of whom were White and middle-aged. Ten-year overall survival for patients with Ph+ CML treated since 2000 was ...